SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter H. Proctor who wrote (116)6/3/1997 12:31:00 AM
From: Vip   of 670
 
Dr. P.: Perhaps you are right about Graftcyte. But the wound treatment product Iamin that needs to be sold through a major medical sales force. But the way I see it the company will need approxiamately $12 million in sales of their products to break enven. The market ain't buying those kind of numbers. As per the Investor Relations Person Karen Hedine: Procyte does not consider itself to be a biotechnology company. The company is a medical company. So without the Tricomin product in Phase III there is a lacking of speculative appeal for a hair growth drug.

Vip
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext